ABP 501: Clinical Trials

5 completed. 4 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	4	Completed 4
Phase 1	1	Completed 1

Follow ABP 501: new trials by email Literature Review of ABP 501 trials Research Report on ABP 501

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis Adalimumab, ABP 501 - Plaque Psoriasis	Phase 3	Completed	Amgen	425	2021-10-04	2024-02-09
Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants ABP 501, Adalimumab - Healthy Volunteers	Phase 1	Completed	Amgen	179	2014-11-24	2023-08-16
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis ABP 501 - Arthritis, Rheumatoid	Phase 3	Completed	Amgen	467	2014-04-01	2017-04-24
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis Adalimumab, ABP 501 - Psoriasis	Phase 3	Completed	Amgen	350	2013-10-18	2019-04-03
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis ABP 501, Adalimumab - Arthritis, Rheumatoid	Phase 3	Completed	Amgen	526	2013-10-01	2016-12-13

Conditions studied

Arthritis (2)  ·  Arthritis, Rheumatoid (2)  ·  Psoriasis (1)

Sponsors

Amgen (5)

Countries

Canada (4)  ·  Germany (3)  ·  United States (3)  ·  Hungary (2)  ·  Poland (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Latvia (1)  ·  Romania (1)  ·  Russia (1)  ·  Spain (1)

Results publications

PMID 33263165, PMID 28584187, PMID 28755394, PMID 30922373, PMID 41954860